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Abstract: Bone metastases play an important role in the morbidity
and mortality of patients with malignant disease. Despite therapeutic
advances in the treatment of solid organ malignancy such as lung
cancer, less development on metastasis interventions has been forth-
coming. More recent research has focused on molecular pathway
manipulation in the prevention and treatment of metastatic bone
disease and associated complications such as bone pain and hyper-
calcemia. The osteoprotegerin/receptor activator of nuclear fac-
tor- ligand/receptor activator of nuclear factor- pathway,
which is physiologically involved in bone turnover, has been of
considerable interest, and recent promising data have been revealed.
In this study, we describe this molecular pathway in terms of its
natural physiological function, manipulation for therapeutic benefit,
and recent clinical trial results.
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More than 1.5 million patients with cancer worldwideexperience bone metastases that are most commonly
associated with cancers of the prostate, breast, and lung,
where, in particular, 30 to 40% and 50% of patients with lung
cancer develop bone metastases at some point or have bone
involvement at the time of diagnosis, respectively.1 Further-
more, postmortem studies have shown that approximately
75% of patients with these cancers have bone metastasis at
death2–4 and approximately therapies directed at this process
have potential to offer huge benefit in terms of morbidity,
hospital admissions, and financial cost and may even improve
survival in this large group of patients. One area of continued
advancement in the prevention and treatment of bone metas-
tases is the osteoprotegerin (OPG)/receptor activator of nu-
clear factor- ligand (RANKL)/receptor activator of nuclear
factor- (RANK) pathway.
Since the discovery of these members of the tumor
necrosis factor (TNF) and TNF receptor superfamily approx-
imately a decade ago, OPG, RANKL, and RANK have all
been found as a unit to have a key role in osteoclast function
and thereby bone turnover.5,6 They are specifically involved
in osteoclastic proliferation, differentiation, activation, and
apoptosis and have also been implicated in lactation, tumor
cell proliferation, and dendritic cell maturation.6,7
RANK is a type I homotrimeric transmembrane protein
which shows high homology with CD40 and is not only
expressed widely on osteoclasts, T and B cells, fibroblasts,
dendritic cells, and mammary gland but also on cancer cells
including breast and prostate.8–11 It has an important role in
bone turnover highlighted by the fact that RANK knockout
mice are profoundly osteopetrotic due to an absence of
osteoclasts.
RANKL is a potent osteoclastogenic factor expressed
as a type II homotrimeric transmembrane protein on osteo-
blasts, osteocytes, and marrow stromal cells, which has 30%
homology to TNF-related apoptosis inducing ligand (TRAIL)
and 20% homology to fas ligand.10,12,13 It interacts with
RANK on the osteoclast membrane and/or OPG, a soluble
decoy receptor. It is also secreted as a soluble molecule by
activated T lymphocytes.14 It was originally described by four
separate research groups. Two of the groups believed
RANKL’s important role lay in the immune system, whereas
the other two groups believed RANKL’s importance was in
osteoclastgenesis.5 RANKL knockout mice have severe os-
teopetrosis with a complete absence of osteoclasts. They also
have defects in early differentiation of T and B cells, lack
lymph nodes, and have defects in mammary gland develop-
ment highlighting “crosstalk” between the immune and skel-
etal systems.5,8,14
OPG is a secreted protein lacking a transmembrane
domain produced by many cell types including bone marrow
stromal cells and osteoblasts, which blocks osteoclast precur-
sor differentiation by binding RANKL (thus preventing
RANK activation).6 OPG’s role as a bone protector has been
demonstrated not least by the fact that OPG knockout mice
have osteoporosis.15,16 OPG is also a soluble decoy receptor
for TRAIL.17,18 In binding TRAIL, it prevents this ligand
from inducing apoptosis of malignant or transformed cells
ultimately enhancing tumor cell survival.18
In humans, mutations in all three members of this
pathway have been discovered. Three RANKL mutations
(V277WfX5, M199K, and dell45–177AA) have been de-
scribed in individuals with autosomal recessive osteopetrosis
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and osteoclast absence.5,19,20 Seven RANK mutations (G53R,
R129C, R170G, C175R, G280X, W434X, and A244S) have
been described in patients with osteoclast deficient osteo-
petrosis.5,20,21 Several OPG mutations have been described
in clinical reports where genetic deletion or abnormality is
associated with juvenile Paget’s disease and idiopathic
hyperphosphatasia.22,23
After the critical role of OPG/RANKL/RANK was
highlighted, for example, in their respective knockout
mice, research soon focused on this pathway in bone
disease. Many factors that were already known to influence
bone turnover, such as parathyroid hormone-related pro-
tein, Vitamin D3, TNF-a, interleukin-1b, prostaglandin E2,
and macrophage colony stimulating factor, have subse-
quently been found to up-regulate/down-regulate one or
more members of this pathway.5,24
Once RANKL binds to RANK, a host of reactions follow
which promote the survival, differentiation, and activation of
mature osteoclasts.6 Importantly, as RANK is also expressed on
tumor cells, it facilitates similar tumor cell responses.25
The binding of RANKL to RANK on the cell mem-
brane leads to receptor trimerization (Figure 1). This results
in the recruitment of adaptor molecules such as tumor necro-
sis factor receptor-associated factor (TRAF)-6 which stimu-
lates the mitogen-activated protein kinase pathways (c-Jun
N-terminal kinase [JNK1], extracellular signal regulated ki-
nase 1, and p38) and the nuclear factor kappa-light-chain-
enhancer of activated B cell (NF-B) pathway through tissue
growth factor--activated kinase. Stimulation of JNK1 re-
sults in the mobilization and activation of osteoclastogenic
transcription factors such as c-Fos, fos-related antigen-1, and
nuclear factor-activated T-cell c1.26 Stimulation of both the
NF-B and JNK pathways are crucial for monocytic precur-
sor differentiation into osteoclasts.26 RANK signaling of
NF-B and JNK pathways is synergistically enhanced by the
binding of TNF-a to tumor necrosis factor receptor-1 which is
facilitated through receptor-interacting protein 1-IB kinase
and TRAF2-GCK complex activation, respectively.26 TRAF6
also interacts with c-Src stimulating the phosphoinositide
3-kinase-Akt pathway thus influencing osteoclast cytoskeletal
changes and survival.27
The interaction of RANKL with OPG and their respec-
tive concentrations has a direct relationship with the levels of
FIGURE 1. The OPG/RANKL/RANK pathway as a therapeutic target. OPG, osteoprotegerin; RANKL, receptor activator of nu-
clear factor- ligand; RANK, receptor activator of nuclear factor-.
Journal of Thoracic Oncology • Volume 6, Number 9, September 2011 The OPG/RANKL/RANK Pathway
Copyright © 2011 by the International Association for the Study of Lung Cancer 1469
bone resorption, and in the case of cancer, growth of bone
metastasis.6 Furthermore, RANKL-stimulated osteoclastic
bone resorption leads to the release of growth factors such as
tissue growth factor- and platelet-derived growth factor,
which in turn stimulate further tumor cell growth through a
positive feedback mechanism.6 RANKL is also up-regulated
through parathyroid hormone-related protein, which is re-
leased with hormones, chemokines, cytokines, and growth
factors by the tumor cells themselves.6 In contrast, T-cell-
produced RANKL can also stimulate osteoclasts to express
interferon- through c-Fos, negatively regulating osteoclast
formation.28
The OPG/RANKL/RANK system has been widely
studied in multiple myeloma-related bone disease where
osteolytic bone lesions are associated with pain, hypercal-
cemia, and pathological fractures.6 An imbalance in the
RANKL/OPG ratio favoring osteolysis has been demon-
strated.6 Moreover, it has become clear that the RANKL/
OPG ratio is a key determinant of bone mass in a variety
of disorders.29,30
RANKL has also been implicated in skeletal metastasis
secondary to solid organ tumors such as lung, breast, and
prostate. The osteolytic lesions and hypercalcemia are asso-
ciated with excessive osteoclast activation mediated by
RANKL-RANK interactions.6 Moreover, Huang et al.31 dem-
onstrated RANKL mRNA and protein in 90% of skeletal
lesions in patients with metastasis from lung, breast, thyroid,
and prostate cancer. OPG levels and OPG/RANKL ratios
have been measured in various cancers and their levels
correlate with the degree of bone metastasis.32,33
The findings of the research into RANKL and its
pathway has led to the emergence of a hypothesis which
suggests that the RANKL/RANK system is a prominent
“soil” factor in promoting metastasis to bone which is high-
lighted by the fact that addition of RANKL to RANK ex-
pressing prostate and breast cancer cell lines influences their
migration.5,34 Moreover, Maspin, a known metastasis sup-
pressor of prostate epithelial cells, is inhibited by RANK
stimulation.35 The value of manipulating this pathway in the
treatment of metastatic disease has been acknowledged by the
extensive research performed over the last decade.
OPG therapy had been shown in mouse models to
inhibit osteoclastogenesis and tumor growth, osteolysis in
multiple myeloma, bone metastasis in prostate cancer, pros-
tate tumor growth, cancer-induced skeletal destruction, and
prevent and reverse malignancy-related hypercalcemia and
diminishing advanced bone cancer pain.36–43
RANK-Fc has been used in mouse studies as a blocking
agent for RANKL and has been shown to diminish tumor
burden in prostate cancer and has therapeutic benefit in
myeloma.44–46
Denosumab is an IgG2 monoclonal antibody with a
long half-life which binds RANKL with high affinity. It was
developed with the aim of treating bone disease primarily
mediated by osteoclast activity such as multiple myeloma,
bone metastasis, and cancer treatment-induced bone loss.47
It has undergone phase II and III clinical trials for
postmenopausal osteoporosis, solid organ bone metastases
(including lung), treatment-induced bone loss in prostate
cancer, and breast/prostate cancer-related metastases and has
shown efficacy in the management of these conditions. It has
also been effective in bone loss associated with adjuvant
aromatase inhibition for breast cancer.48–55
These trials included a randomized double-blind, phase
III clinical trial in 2046 women with bone metastases from
breast cancer comparing the safety and efficacy of subcuta-
neous monthly denosumab with monthly intravenous zole-
dronic acid and found that denosumab was superior to zole-
dronic acid in delaying time to first on-study skeletal-related
event (SRE) (Table 1).56
Similar findings have been demonstrated in patients
with castration-resistant prostate cancer with established bone
metastases in a phase III trial involving 1904 men compariny
denosumab with zoledronic acid.57
Zoledronic acid (Zometa) is a nitrogenous bisphospho-
nate that disrupts the HMG-CoA reductase pathway by bind-
ing farnesyl diphosphate synthase. This results in the inhibi-
tion of protein prenylation and the lipid modification of Ras,
Rac, and Rho proteins essential to the osteoclast. In particu-
lar, these proteins are key to cell survival, osteoclastogenesis,
and cytoskeletal arrangement. Although both the HMG-CoA
reductase and OPG/RANK/RANKL pathways are physiolog-
ically involved in bone turnover, the OPG/RANK/RANKL
pathway is thought to play a more central role in bone
metastasis highlighted by preclinical research and in vivo
work demonstrating increased expression of the RANK/
RANKL proteins and abnormal OPG/RANKL ratios in
patients with cancer with bone metastases (unlike in the
case of the HMG-CoA pathway), possibly explaining the
increased therapeutic benefit/targeting of this system in
malignant disease.5,32–34
Denosumab also has other important practical advan-
tages over bisphosphonate therapy. It is given every 4 weeks
as a 120 mg subcutaneous injection, whereas zoledronic acid
is administered every 4 weeks through a 15-minute intrave-
nous infusion, requiring significant resource input that may
not be widely available. In addition, adverse events are less
frequent with denosumab and importantly unlike zoledronic
acid, renal function does not need to be monitored.56,58
With regard to lung cancer, a randomized, double-blind
study of denosumab versus zoledronic acid in the treatment of
bone metastases in 1776 patients with advanced cancer (ex-
cluding breast and prostate cancer) or multiple myeloma has
yielded some interesting results. This study was made up of
approximately 10% myeloma, 40% non-small cell lung can-
cer, and 50% other solid organ cancers (excluding prostate
and breast). Denosumab was noninferior (trend toward supe-
riority) to zoledronic acid in preventing or delaying first
on-study SRE in patients with advanced cancer metastatic to
bone or myeloma.58 A subset analysis of the same study,
which was presented at the American Society of Clinical
Oncology 2010 annual meeting, analyzed the treatment data
only in solid-tumor patients with bone metastases (of which
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non-small cell lung cancer was almost half) and found that
denosumab significantly delayed the time to the first and
subsequent SREs compared with zoledronic acid.59 These
data support further trials into the use of this agent in solid
organ malignancy, particularly lung cancer.
Denosumab has also been investigated in the preven-
tion of metastases, specifically, with a randomized, placebo-
controlled multicenter phase III trial comparing the effect of
denosumab with placebo on bone metastasis-free survival in
men with hormone refractory (castrate-resistant) prostate can-
cer with rising prostate-specific antigen levels who were free
of bone metastasis at enrolment. This study involving 1432
men demonstrated a significantly increased median bone
metastasis-free survival of 4.2 months and an improved time
to first occurrence of bone metastasis in the treated group.5,60
This antibody has recently been approved in the Euro-
pean Union and United States for the treatment of osteopo-
rosis and bone disease (single or multiple metastases) asso-
ciated with solid organ cancer.5 Further information on the
ongoing phase III trials involving denosumab can be found at
www.clinicaltrials.gov. They include three trials in prostate
cancer (NCT00321620, NCT00089674, and NCT00286091),
two trials in breast cancer (NCT00321464 and NCT00556374),
and one trial in solid organ tumors and multiple myeloma
(NCT00330759) (Table 1).59
Other phase III trials are planned including Study
NCT01077154—Denosumab as Adjuvant Treatment for
Women With High Risk Early Breast Cancer Receiving
Neoadjuvant or Adjuvant Therapy. This randomized phase III
trial will study the effect of denosumab to see if it can prevent
disease recurrence in the bone or in any other part of the
body, when it is given as adjuvant therapy for women with
early-stage breast cancer, who are at high risk of disease
recurrence. This study is currently recruiting patients.61
Pathway manipulation may not just provide benefit in
patients with bone metastases. Solid organ cancer and lung
metastases may also be directly targeted in the future. Sch-
ramek et al.62 demonstrated that medroxyprogesterone acetate
can induce RANKL expression in the mammary gland to an
enormous extent. RANKL overexpression leads to an accel-
eration of mammary gland preneoplasias with increased tu-
mor formation after multiparity or treatment with progestins
and carcinogens.63 Inhibiting RANKL in this scenario may
offer direct solid tumor suppression.
Tan et al.64 have very recently demonstrated that
RANK signaling in mammary carcinoma enhances metastasis
to lung in mice and therefore targeting the OPG/RANKL/
RANK pathway may not just benefit patients with bone
metastasis but may have therapeutic benefit in lung metastasis
also, although further research is required.
Clearly, our understanding of the OPG/RANKL/RANK
pathway and its involvement in bone turnover and bone
metastasis has evolved over the past decade, made obvious by
the number of phase III clinical trials performed and currently
running. More recent developments such as its direct role in
cancer cell growth and migration (e.g., to the lung) offer huge
therapeutic potential once the process has been further
unraveled.
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